Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson’s and Rare Epilepsy Research
Lunai Bioworks' subsidiary BioSymetrics and BrainStorm Therapeutics have begun a foundation-funded collaboration to discover and validate new therapeutic targets for neurological diseases, integrating AI discovery with organoid and in vivo validation platforms.